

Karin B Mirzaev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6848983/publications.pdf>

Version: 2024-02-01

48
papers

227
citations

1170033

9
h-index

1255698

13
g-index

53
all docs

53
docs citations

53
times ranked

257
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy, 2022, 37, 41-46.	0.3	2
2	Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. British Journal of Clinical Pharmacology, 2021, 87, 725-729.	1.1	1
3	Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results. Meditsinskiy Sovet, 2021, , 41-46.	0.1	1
4	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy, 2021, .	0.3	0
5	MicroRNAs as Novel Biomarkers for P2Y12 “Inhibitors Resistance Prediction. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1575-1582.	0.4	3
6	CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups. Terapevticheskii Arkhiv, 2021, 93, 1334-1339.	0.2	0
7	Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. Pharmacogenomics, 2020, 21, 677-694.	0.6	6
8	<p>CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban</p>. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 29-37.	0.4	10
9	Drug“drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metabolism and Personalized Therapy, 2020, .	0.3	5
10	Is it possible to use riamilovir to prevent infection and treat COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 15-17.	0.2	3
11	Rationale for use mefloquine for COVID-19 treatment. Kachestvennaya Klinicheskaya Praktika, 2020, , 103-105.	0.2	0
12	Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika, 2020, , 115-119.	0.2	3
13	Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 18-22.	0.2	3
14	Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab. Kachestvennaya Klinicheskaya Praktika, 2020, , 23-27.	0.2	1
15	Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 32-34.	0.2	0
16	Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for “cytokine storm” therapy. Kachestvennaya Klinicheskaya Praktika, 2020, , 4-7.	0.2	0
17	What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?. Kachestvennaya Klinicheskaya Praktika, 2020, , 47-49.	0.2	1
18	Could canakinumab be used for COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 50-52.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 53-59.	0.2	0
20	Current and future use of umifenovir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 75-80.	0.2	1
21	Possibility for the use of bromhexine to prevent infection with SARS-CoV-2. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 8-10.	0.2	0
22	Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 90-91.	0.2	1
23	Current and future use of dipyridamole in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 92-95.	0.2	1
24	Dexamethasone use in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 96-98.	0.2	0
25	Current and future use of remdesivir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 99-102.	0.2	0
26	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	4
27	Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population. <i>Rational Pharmacotherapy in Cardiology</i> , 2019, 15, 393-406.	0.3	14
28	ADME pharmacogenetics: future outlook for Russia. <i>Pharmacogenomics</i> , 2019, 20, 847-865.	0.6	12
29	Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.3	5
30	Genotyping and phenotyping CYP3A4/CYP3A5: no association with antiplatelet effect of clopidogrel. <i>Molecular Biology Reports</i> , 2019, 46, 4195-4199.	1.0	3
31	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 299-306.	0.2	1
32	Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 699-702.	0.3	1
33	Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking β_2 -blockers in the Republic of Sakha (YAKUTIA). <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 195-200.	0.3	7
34	NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 47-52.	0.3	0
35	The <i>ABCB1</i> , <i>CYP2C19</i> , <i>CYP3A5</i> and <i>CYP4F2</i> genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 109-118.	0.3	7
36	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A <i>CYP2C19</i> gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 91-98.	0.3	6

#	ARTICLE	IF	CITATIONS
37	The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 127-137.	0.4	34
38	Personalisation of antiplatelet therapy and secondary prevention of ischemic stroke.. <i>Klinicheskaia Meditsina</i> , 2018, 96, 677-687.	0.2	0
39	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 747-753.	0.3	14
40	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 129-136.	0.3	17
41	Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 93-99.	0.4	11
42	CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 107-114.	0.4	14
43	Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 243-245.	0.4	4
44	INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 344-354.	0.3	0
45	GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA. <i>Russian Journal of Cardiology</i> , 2015, , 92.	0.4	2
46	EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 85-91.	0.3	11
47	CYTOCHROME P450 (CYP2C9) ACTIVENESS, EVALUATED VIA LOSARTAN TEST, AS PREDICTION MARKER FOR THE WARFARIN TREATMENT DOSAGE CHOICE IN PATIENTS WITH DELAYED OUTCOMES AFTER HEART VALVES REPLACEMENT. <i>Russian Journal of Cardiology</i> , 2015, , 70.	0.4	0
48	THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 404-408.	0.3	3